Mean platelet volume as a predictive biomarker for in-hospital mortality in patients receiving invasive mechanical ventilation

Yingying Zheng*, Zujin Luo and Zhixin Cao

Abstract
Background: Although mean platelet volume (MPV) has been reported to be associated with poor prognosis of various critical illness, the relationship between MPV and in-hospital mortality among patients undergoing invasive mechanical ventilation (IMV) is unclear.

Methods: A retrospective observational study including patients receiving IMV was conducted from January, 2014 to January, 2019. The patients were divided into two groups by MPV cutoff value. The receiver operating characteristics curve was used to evaluate the predictive ability of MPV for in-hospital mortality. Univariate and multivariate Cox regression analysis were conducted to analyze the value of MPV for predicting in-hospital mortality. Kaplan–Meier cumulative incidence curve was employed to observe the incidence of in-hospital mortality.

Results: A total of 274 patients were enrolled in the study, and 42 patients (15.3%) died in hospital. MPV > 11.4 fl was a valuable predictor for in-hospital mortality (AUC 0.848; 95%CI, 0.800–0.889) with sensitivity 66.7%, and specificity 86.21%. MPV > 11.4 fl was an independent risk factor for in-hospital mortality (adjusted HR 2.640, 95%CI, 1.208–5.767, \(P = 0.015\)). Compared to the group of MPV ≤ 11.4 fl, patients with MPV > 11.4 fl had increased mortality (log-rank test = 40.35, HR = 8.723, \(P < 0.0001\)). The relationship between MPV and in-hospital mortality was stronger in female patients than in male patients.

Conclusion: MPV > 11.4 fl is a more useful marker for predicting in-hospital mortality among critically ill patients receiving IMV, especially in female patients. Attention to the MPV marker is simple and profitable with immediate applicability in daily clinical practice.

Keywords: Mean platelet volume, Invasive mechanical ventilation, In-hospital mortality

Introduction
Mechanical ventilation is frequently used for life support for patients experiencing respiratory failure or undergoing general anesthesia in critical illness. These patients are at risk for a number of complications related to both their underlying disease state and the mechanical ventilation itself [1]. Some studies evaluating patients requiring mechanical ventilation have reported mortality rates from 12 to 40% [2–9] according to different diseases. Therefore, early predictions of mortality and intervention are of great importance for improving the prognosis of patients. Acute Physiology and Chronic Health Evaluation II (APACHE II) score, solid tumor, severe sepsis/septic shock, acute lung injury/acute respiratory distress syndrome, and acute kidney injury have been reported as predictors of hospital mortality [9]. However, the relationship...
between inflammation markers and hospital mortality among those adult patients receiving IMV were lacking. Hence, it is critical to explore the predictive ability of inflammation markers for hospital mortality for those patients.

It has been reported that platelet has increasing focus for its role in inflammation and immunity [10]. Mean platelet volume (MPV), a routinely measured marker in clinical practice, is a simple, easy, available, and accurate indicator of platelet size and function [11]. Numerous studies have demonstrated that MPV levels or the change of MPV were correlated with serious complication or poor prognosis for ICU patients [12, 13], sepsis [14, 15], influenza pneumonia [16], acute pulmonary embolism [17]. In addition, MPV also has been shown to be a valuable prognostic marker for patients following acute abdominal surgery [18], chronic obstructive pulmonary disease (COPD) patients [19], coronary artery disease [20] and Type 2 Diabetes Mellitus [21].

Critically ill patients experiencing invasive mechanical ventilation (IMV) are generally in a high state of inflammation, strong stress, and immunity response [22], which may be related to both their underlying disease state, endotracheal intubation and the mechanical ventilation itself [1]. Nonsurvivors may suffer more inflammatory response and stress. However, there were few studies focusing on the inflammation markers and in-hospital mortality among critically ill adult patients receiving IMV.

Accordingly, we assumed that higher MPV could be related with higher in-hospital mortality. And we evaluated the effectiveness of MPV for predicting hospital mortality in patients receiving IMV.

Methods
Study population
This retrospective, observational, single center study included patients receiving IMV not less than 24 h admitted to the ICU of Beijing Chao-Yang Hospital from January, 2014 to January, 2019. The following patients were excluded: Age < 18 years; pregnancy; tracheotomy or other upper airway disorders; mechanically ventilated less than 24 h; neuromuscular disease; decision to abandon or limit active treatment; incomplete data [23].

This study (NO.2020-KE-94) was approved by the Ethics Committee of the Beijing Chao-Yang Hospital, Capital Medical University. The requirement for informed consent was waived by the Ethics Committee of the Beijing Chao-Yang Hospital, Capital Medical University because of the retrospective nature of the study. All procedures were in accordance with Helsinki Declaration.

Data collection
Patients’ demographic and baseline characteristics were recorded within 24 h after intubation, including age, sex, body mass index (BMI), acute physiology and chronic health evaluation II (APACHE II) score, basic vital signs, arterial blood gas and laboratory data. The following were also recorded: comorbidities and acute causes of IMV, IMV duration, complication, length of stay (LOS) in ICU, LOS in hospital, and in-hospital mortality. Albumin (ALB), alanine aminotransferase (ALT), aspartate aminotransferase (AST), blood creatinine, complete blood cell counts and CRP within 24 h after intubation were measured. Complete blood cell counts were measured by an automatic blood analyzer. CRP concentrations were measured using immunosscatter turbidimetry by Goldsite Aristo (Goldsite, Ltd., China), and the normal value of CRP ranges from 0 to 5 mg/L [23]. Acute kidney injury (AKI), defined according to established criteria [24]; septic shock, defined according to established criteria [25]. Gastrointestinal bleeding was defined as any clinically suspected or documented of bleeding from the gastrointestinal tract as indicated with a fall in hemoglobin level and the appearance of melena, haematemesis or stool tested positive for occult blood [26]. Acute liver dysfunction was defined as abnormality of the AST and ALT. Acute coronary syndrome included the event of acute ST elevation or non-ST elevation myocardial infarction or unstable recurrent angina as indicated by the typical symptom with abnormal ECG or echocardiography or myocardial enzyme elevation. Acute cerebrovascular disease included haemorrhagic stroke, ischaemic stroke and transient ischaemic attack which were diagnosed or suspected by neurologist according to symptoms and computerized tomography of brain.

Clinical outcome
The primary outcome was in-hospital mortality rate, which was defined as deaths occurring during hospitalization. Survivors were discharged to homes or transferred to another hospital.

Statistics
Continuous variables were expressed as mean ± standard deviation (SD) for normality distribution or median (25th-75th percentile) for nonnormally distributed data.

The Kolmogorov–Smirnov test was used for the normality distribution. Student’s t test was employed for normally distributed data. The Mann–Whitney U-test was used for nonnormally distributed data. Categorical data was expressed as frequency and percentages, and Chi square (χ2) test was performed. Spearman correlations were used for correlation analysis between MPV...
and other variables. A univariate Cox regression analysis was constructed to explore the association between patients’ characteristics and in-hospital mortality. The multivariate Cox regression with the enter method was also employed to examine variables significantly associated with in-hospital mortality in the univariate analysis, including covariates: APACHE II score, MPV, PaO2/FIO2, vasopressor use, CRRT, CKD, AKI, and septic shock, which resulted in adjusted hazard ratios (HR, 95%CI). In Cox models, time at risk was from study entry until death during hospitalization, discharge, or transfer. Furthermore, the receiver operating characteristic (ROC) analysis was used to evaluate the sensitivity and specificity of MPV for predicting in-hospital mortality and to determine the optimum cutoff value. Cumulative survival curves were conducted by Kaplan–Meier method and differences between groups were evaluated by log-rank test. All analyses were two-tailed, and a probability value (p value) less than 0.05 was considered statistically significant. All data were done using SPSS (Statistical Package for the Social Science; SPSS Inc., Chicago, IL, USA) version 22 for Microsoft Windows.

Results

Patients’ characteristics and outcomes

A total of 274 patients were enrolled in the study, as shown in Fig. 1. Of these, 42 patients (15.3%) died in hospital. According to the optimal cutoff value of MPV predicting in-hospital mortality, baseline characteristics and outcomes were summarized in Table 1. Compared with patients with MPV \( \leq 11.4 \) fl, patients with MPV > 11.4 fl had higher APACHE II score, increased frequency of patients with congestive heart failure, and immunosuppression, longer ICU LOS, much more complications including septic shock, AKI, acute liver dysfunction, gastrointestinal bleeding, and acute coronary syndrome, higher frequency treatment of vasopressor use and CRRT. Moreover, patients with MPV > 11.4 fl showed lower PaO2/FIO2, lower platelet count, higher lactate, higher PDW, higher larger platelet ratio, and higher CRP level. The hospital mortality rate was higher in patients

---

**Fig. 1** Flow chart of patient selection and outcome. Note: high group: MPV > 11.4 fl; low group, MPV \( \leq 11.4 \) fl; ROC, receiver operating characteristic curve; ICU, intensive care unit.
| Characteristics                             | MPV > 11.4 fl (n = 60) | MPV ≤ 11.4 fl (n = 214) | P     |
|--------------------------------------------|------------------------|-------------------------|-------|
| Age, year (mean ± SD)                      | 72.75 ± 11.24          | 70.77 ± 13.52           | 0.300 |
| Male, n (%)                                | 37 (61.67)             | 123 (53.02)             | 0.561 |
| BMI, kg/m² (mean ± SD)                     | 24.02 ± 3.42           | 24.31 ± 4.71            | 0.597 |
| APACHE II score, (mean ± SD)               | 21.02 ± 6.67           | 18.44 ± 6.96            | 0.007 |
| IMV duration, days (median, 25th–75th percentiles) | 7 (4–16)                | 4 (1–9.25)              | 0.053 |
| ICU LOS, days (median, 25th–75th percentiles) | 17 (10–32)              | 10 (3–20)               | 0.000 |
| H LOS, days (median, 25th–75th percentiles) | 21 (15.25–40.75)       | 19 (13–28)              | 0.069 |
| Cause of mechanical ventilation, n (%)     |                        |                         |       |
| Exacerbation of chronic respiratory disorders | 15 (25)                 | 37 (17.29)              | 0.178 |
| Pneumonia                                  | 18 (30)                | 62 (28.97)              | 0.887 |
| Sepsis                                     | 12 (20)                | 43 (20.09)              | 0.987 |
| Postoperation                              | 8 (13.33)              | 52 (24.30)              | 0.070 |
| Congestive heart failure                   | 4 (6.67)               | 3 (1.40)                | 0.040 |
| Neurological disease                       | 2 (3.33)               | 12 (5.61)               | 0.741 |
| others                                     | 1 (1.67)               | 5 (2.34)                | 1.000 |
| Comorbidity disease, n (%)                 |                        |                         |       |
| Hypertension                               | 36 (60)                | 114 (53.27)             | 0.335 |
| Diabetes Mellitus                          | 23 (38.33)             | 54 (25.23)              | 0.050 |
| Chronic heart disorders                    | 21 (33)                | 64 (29.9)               | 0.451 |
| Chronic respiratory disorders              | 19 (31.67)             | 61 (28.5)               | 0.634 |
| Malignancy                                 | 14 (23.33)             | 49 (22.90)              | 0.943 |
| Chronic kidney disease                     | 11 (18.33)             | 22 (10.28)              | 0.090 |
| Cerebrovascular disease                    | 10 (16.67)             | 33 (15.42)              | 0.815 |
| Immunosuppression                          | 3 (5)                  | 1 (0.46)                | 0.034 |
| Clinical outcome, n (%)                    |                        |                         |       |
| Septic shock                               | 25 (41.67)             | 41 (19.16)              | 0.000 |
| Acute renal injury                         | 29 (48.33)             | 41 (19.16)              | 0.000 |
| Gastrointestinal bleeding                  | 18 (30)                | 36 (16.82)              | 0.023 |
| Acute liver dysfunction                    | 26 (43.33)             | 61 (28.50)              | 0.029 |
| Acute coronary syndrome                    | 8 (13.33)              | 12 (5.61)               | 0.042 |
| Acute cerebrovascular disease              | 3 (5)                  | 8 (3.74)                | 0.710 |
| Vasopressor use                            | 19 (31.67)             | 39 (18.22)              | 0.024 |
| CRRT                                       | 3 (5)                  | 11 (5.14)               | 1.000 |
| Sedation                                   | 46 (76.67)             | 146 (68.22)             | 0.207 |
| Hospital mortality                         | 28 (46.67)             | 14 (6.54)               | 0.000 |
| Laboratory findings                        |                        |                         |       |
| RR, breaths/min                            | 21.10 ± 5.252          | 19.83 ± 4.712           | 0.074 |
| SpO2, %                                    | 98 (96.25–100)         | 99 (97.75–100)          | 0.057 |
| HR, beats/min                              | 87.70 ± 15.358         | 87.44 ± 14.794          | 0.907 |
| SBP, mmHg                                  | 130.38 ± 18.94         | 129.50 ± 21.98          | 0.778 |
| PH                                         | 7.45 (7.42–7.48)       | 7.45 (7.42–7.48)        | 0.718 |
| PaCO2, mmHg                                | 54.5 (45.95–71)        | 50 (44.3–60.7)          | 0.054 |
| PaO2, mmHg                                 | 89 (78.65–95)          | 89 (80–101.5)           | 0.148 |
| PaO2/FiO2, mmHg                            | 153.87 (130.26–172.86) | 161.82 (138.33–187.38)  | 0.035 |
| Lactate, mmol/L                            | 1.6 (1.2–2.5)          | 1.3 (1.00–1.7)          | 0.002 |
| Hemoglobin, g/L                            | 93.13 ± 24.90          | 99.10 ± 21.73           | 0.070 |
| Albumin, g/L                               | 26.08 ± 6.12           | 27.53 ± 6.65            | 0.130 |
| Creatinine                                 | 88.85 (55.43–125.30)   | 74 (57.4–117.3)         | 0.363 |
| ALT, IU/L                                  | 23 (16.63–32.5)        | 19.15 (13–34.65)        | 0.100 |
with MPV > 11.4 fl than those with MPV ≤ 11.4 fl (46.67% vs 6.54%, \( P = 0.000 \)).

### Relationship between MPV and other variables

By the correlation analysis as shown in Fig. 2, MPV was positively related with CRP (\( r = 0.231, \ P = 0.000 \)), APACHE II score (\( r = 0.238, \ P = 0.000 \)), while it was negatively correlated with platelet count (\( r = -0.205, \ P = 0.001 \)) and \( \text{PaO}_2/\text{FiO}_2 \) (\( r = -0.171, \ P = 0.005 \)).

### Risk factors for in-hospital mortality

The possible risk factors for higher in-hospital mortality were shown in Table 2. After adjusting for covariates (\( P < 0.05 \) in univariate Cox regression), the multivariate

### Table 1 (continued)

| Characteristics          | MPV > 11.4 fl (n = 60) | MPV ≤ 11.4 fl (n = 214) | \( P \) |
|--------------------------|------------------------|-------------------------|--------|
| AST, IU/L                | 32.55 (21.18–53.75)    | 26.9 (18.5–43.05)       | 0.095  |
| Leukocyte count, × 10⁹/L | 10.25 (8.25–12.05)     | 9.7 (6.9–12.65)         | 0.546  |
| Neutrophil count, × 10⁹/L| 7.52 (5.82–9.84)       | 8.29 (5.8–11.74)        | 0.380  |
| Lymphocyte count, × 10⁹/L| 0.73 (0.5–1.07)        | 0.79 (0.53–1.29)        | 0.303  |
| Platelet count, × 10⁹/L  | 148 (107.5–202.75)     | 184 (134.75–254.5)      | 0.003  |
| PDW, %                   | 14.45 (11.53–16.48)    | 12 (10.5–12.925)        | 0.000  |
| Platelet large cell ratio,%| 34.02 ± 9.90           | 27.44 ± 7.74            | 0.000  |
| CRP, mg/L                | 70.5 (34.5–109.5)      | 44.5 (18.75–84.0)       | 0.002  |

Continuous variables were presented as median (25th-75th percentile) or (mean ± SD). Categorical variables were presented as numbers (n) and percentages (%). 

**BMI** body mass index; APACHE II acute physiology and chronic health evaluation II; IMV invasive mechanical ventilation; LOS length of stay; RR respiratory rate; HR heart rate; SBP systolic blood pressure; SPO\(_2\) peripheral oxygen saturation; PaCO\(_2\) arterial carbon dioxide tension; PaO\(_2\) arterial oxygen tension; FiO\(_2\) fraction of inspired oxygen; MPV mean platelet volume; PDW platelet distribution width; CRP C-reactive protein; CRRT continuous renal replacement therapy; ALT alanine aminotransferase; AST aspartate aminotransferase

![Fig. 2](image-url) 

**Fig. 2** Correlations between MPV and other variables. Abbreviate: MPV, mean platelet volume; APACHE II, acute physiology and chronic health evaluation II; \( \text{PaO}_2 \), arterial oxygen tension; \( \text{FiO}_2 \), fraction of inspired oxygen; CRP, C-reactive protein
Cox regression suggested that MPV, PaO₂/FIO₂, CRP and CRRT were associated with in-hospital mortality (P = 0.001, P = 0.015, P = 0.008 and P = 0.005 respectively).

Predicting ability of MPV for in-hospital mortality
As shown by ROC curves (Fig. 3), the cutoff value of MPV for predicting in-hospital mortality was 11.4 fl with a sensitivity of 66.67%, a specificity of 86.21% and diagnostic accuracy of 83.21%, and had a moderate power for predicting in-hospital mortality (AUC 0.848; 95%CI, 0.800–0.889, P < 0.0001).

MPV associated with in-hospital mortality
According to Kaplan–Meier survival curves for the MPV level, patients with MPV > 11.4 fl had clearly higher mortality than those with MPV ≤ 11.4 fl (log-rank chi square test = 40.35, HR = 8.723, P < 0.0001) (Fig. 4).

Associations of MPV with in-hospital mortality were shown in Table 3. After adjusting for covariates, Cox regression analysis indicated that patients with MPV > 11.4 fl was significantly related to higher in-hospital mortality. In model 3 with the maximum covariates including age, sex, APACHE II score, PaO₂/FIO₂, vasopressor use, CRRT, CKD, AKI, septic shock, albumin, creatinine, leukocyte, and CRP, adjusted HR for in-hospital mortality was 2.640 (95%CI, 1.208–5.767, P = 0.015).

Relationship between mortality and MPV in the sex subgroup
A subgroup analysis by sex was conducted using Cox model after adjusting covariates including APACHE II score, CRP, PaO₂/FIO₂, vasopressor use, CRRT, CKD, AKI, septic shock, albumin, creatinine, leukocyte, and CRP.

Table 2 Independent predictors of in-hospital mortality by univariate and multivariate Cox regression analysis

| Variables | HR (95%CI) | P      |
|-----------|------------|--------|
| APACHE II score | 1.046 (1.001–1.092) | 0.043  |
| Albumin   | 1.016 (0.963–1.072) | 0.561  |
| Creatinine | 1.001 (1.000–1.002) | 0.214  |
| MPV       | 1.712 (1.358–2.159) | 0.000  |
| Leukocyte | 0.982 (0.908–0.993) | 0.657  |
| CRP       | 1.011 (1.003–1.020) | 0.011  |
| Vasopressor use | 2.087 (1.115–3.908) | 0.021  |
| CRRT      | 3.134 (1.193–8.232) | 0.003  |
| CKD       | 2.052 (1.017–4.140) | 0.045  |
| Septic shock | 2.538 (1.371–4.697) | 0.003  |
| AKI       | 1.949 (1.051–3.612) | 0.034  |
| PaO₂/FIO₂ | 0.982 (0.971–0.993) | 0.002  |
| Age       | 1.028 (1.000–1.057) | 0.052  |
| Lactate   | 1.080 (0.953–1.223) | 0.228  |
| sex       | 0.849 (0.447–1.613) | 0.849  |

* Covariates included in multivariate analysis: APACHE II score, MPV, PaO₂/FIO₂, vasopressor use, CRRT, CKD, AKI, septic shock

APACHE II acute physiology and chronic health evaluation II; MPV mean platelet volume; CRP C-reactive protein; CRRT continuous renal replacement therapy; CKD chronic kidney disease; AKI acute kidney injury; PaO₂ arterial oxygen tension; FIO₂ fraction of inspired oxygen;

MPV, mean platelet volume; ROC, receiver operating characteristic; AUC, area under the curve

Fig. 3 ROC curves of MVP for predicting in-hospital mortality. Abbreviate: MPV, mean platelet volume; ROC, receiver operating characteristic; AUC, area under the curve

Fig. 4 Kaplan–Meier survival curve according to the cutoff value of MPV for in-hospital mortality. MPV, mean platelet volume
AKI, septic shock. In the subgroup analysis, the relationship between MPV > 11.4 fl and in-hospital mortality seemed to be stronger in female subgroup (HR, 14.265; 95%CI: 2.323–87.579; P = 0.004) than that in male subgroup (HR, 2.905; 95%CI: 1.042–8.098; P = 0.042) (Table 4). The Kaplan–Meier curve also suggested that the MPV > 11.4 fl had a greater impact on in-hospital mortality in female patients than in male patients (Fig. 5).

**Discussion**

In this research, we indicated MPV > 11.4 fl within 24 h after IMV was positively associated with in-hospital mortality among patients experiencing IMV. MPV > 11.4 fl with the AUC of ROC (0.848; 95%CI, 0.800–0.889) had a moderate predictive ability for in-hospital mortality and MPV > 11.4 fl was an independent predictor for in-hospital mortality. The HR of MPV > 11.4 fl for predicting mortality was 2.642 after adjusting for potential confounders, suggesting that the mortality risk of patients with MPV > 11.4 fl is much higher than patients with MPV ≤ 11.4 fl. The relationship between MPV > 11.4 fl and in-hospital mortality was stronger in female patients than in male patients.

Some studies had reported the similar results. A study suggested that MPV cutoff > 9,45fL at day 1, > 8,95fL at day 2 and > 8,85fL at day 3 were independent predictor factors of mortality in sepsis [27]. Chen reported that MPV > 10.5 fl were associated with in-hospital mortality in severe pneumonia patients [28]. A retrospective study also found that the elevated MPV was related to poor outcome [29], however they did not find the association between the MPV at admission and in-hospital mortality in ICU patients. In our study, we focused on patients with IMV, and also find MPV > 11.4 fl was associated with in hospital mortality. The cutoff values were different, which may due to the difference in study population, severity of diseases, baseline characteristics, and even adjusted confounders.

The underlying mechanisms of higher MPV with poor prognosis in patients with IMV remain hazy. The

### Table 3 Relationship between MPV level and in-hospital mortality

| In-hospital mortality | MPV > 11.4 fl group |
|-----------------------|---------------------|
|                       | HR (95%CI)          | P       |
| Unadjusted            | 4.30 (2.223–8.317)  | 0.000   |
| Model 1               | 4.245 (2.18–8.266)  | 0.000   |
| Model 2               | 3.996 (1.862–8.578) | 0.000   |
| Model 3               | 2.640 (1.208–5.767) | 0.015   |

Reference group is MPV ≤ 11.4 fl. Model 1: age and sex; Model 2: model 1 plus APACHE II score, PaO2/FiO2, vasopressor use, CRRT, CKD, AKI, septic shock; Model 3: model 2 plus albumin, creatinine, leukocyte, and CRP

**MPV** mean platelet volume; **APACHE II** acute physiology and chronic health evaluation II; **CRP** C-reactive protein; **CRRT** continuous renal replacement therapy; **CKD** chronic kidney disease; **AKI** acute kidney injury; **PaO2** arterial oxygen tension; **FiO2** fraction of inspired oxygen; **HR** hazard ratio; **CI** confidence interval

### Table 4 Relationship between in-hospital mortality and MPV cutoff by sex

| In-hospital mortality | Female HR (95%CI) | P       | Male HR (95%CI) | P       |
|-----------------------|-------------------|---------|----------------|---------|
| MPV > 11.4 fl         | 14.265 (2.323–87.579) | 0.004 | 2.905 (1.042–8.098) | 0.042 |

Covariates included in Cox model: APACHE II score, CRP, PaO2/FiO2, vasopressor use, CRRT, CKD, AKI, septic shock

**MPV** mean platelet volume; **APACHE II** acute physiology and chronic health evaluation II; **CRP** C-reactive protein; **CRRT** continuous renal replacement therapy; **CKD** chronic kidney disease; **AKI** acute kidney injury; **PaO2** arterial oxygen tension; **FiO2** fraction of inspired oxygen; **HR** hazard ratio; **CI** confidence interval

Fig. 5 Kaplan–Meier survival curve according to the cutoff value of MPV for in-hospital mortality in female subgroup (a) and male subgroup (b). MPV, mean platelet volume
findings could be elaborated by several possible reasons as below.

Patients with mechanical ventilations are often critically ill and undergo a more serious status and stronger inflammatory response [30, 31]. Endotracheal intubation and mechanical ventilation can enhance this inflammatory reaction and stress. Moreover, nonsurvivors may experience more local and systemic inflammatory responses and stress. Hence, severe inflammatory response and stress were the possible mechanisms for higher MPV in nonsurvivors, which were induced by underlying disease, endotracheal intubation, and mechanical ventilation.

Some studies suggested that serious inflammation could induce a systematic response with the release of thrombopoietin and lots of proinflammatory cytokines, mainly IL-6 and other substances that stimulate platelet activation and the massive production of young platelets in the blood circulation [27, 32, 33], but these large platelets function poorly competent, inducing thrombogenic activity and adverse clinical outcomes [32]. In the current study, patients with MPV > 11.4 fl had higher APACHE II score, longer ICU LOS, more complications including shock, AKI, acute liver dysfunction, gastrointestinal bleeding, and acute coronary syndrome, higher frequency treatment of vasopressor use and CRRT. Moreover, patients with MPV > 11.4 fl showed lower PaO2/FIO2, higher lactate, and higher CRP level, suggesting that those patients suffer more serious status and show more intense inflammatory response. In addition, a previous study had reported this platelet count was inversely related with MPV [34], in this study patients with MPV > 11.4 fl had a lower platelet count than that in patients with MPV ≤ 11.4 fl. MPV was also negatively associated with platelet count among these patients. We inferred that thrombocyte consumption caused by severe inflammation could result in higher MPV. Besides that, some studies reported that hypoxemia may enhance platelet consumption and promote bone marrow activation. Our study showed that nonsurvivors had much lower PaO2/FIO2, which could be another explanation for the increased MPV levels in nonsurvivors. In all, these factors could result in a higher MPV in nonsurvivors. According, we believe that MPV might be a more useful predicting factor for in-hospital mortality.

Besides that, we also found that the relationship between higher MPV and in-hospital mortality was much stronger in female patients than in male patients, which indicating that MPV was more likely to reflect in-hospital mortality in female patients. This was in line with previous study [28], reporting that MPV was associated with mortality among severe pneumonia female patients. Although it has been reported that there were differences in platelet function between male and female mice [35], the mechanism of the relationship was uncler. Female have higher platelet responsiveness [36], platelet counts [37], and had a higher propensity to activate integrin αIIbβ3, to degranulate and expose P-selectin, and to form platelet–leukocyte aggregates [38]. Women platelets have an intrinsic higher propensity to be activated by inflammatory stimuli compared to men [39]. The sexual dimorphism affects both the pro-aggregating and the immune-modulatory function of platelets [39]. Those may be potential mechanisms. With higher platelet responsiveness and platelet counts, the platelet may release more pro-inflammatory factors and immune regulatory factors, and interact more with granulocytes, leading to more serious inflammatory reactions in female patients. In addition, a study reported that a higher MPV might be a surrogate marker associated with metabolic disturbance only in women [40], which may be another possible mechanism to explain our results. More researches are needed to furtherly confirm this relationship.

Limitations

There were some limitations in this study. First, this is a single-center retrospective study with a small sample, so the results of this study ought to be generalized with caution. Second, we did not investigation nutritional status and antibiotics use which could affect the inflammatory response and in-hospital mortality. Third, there were about 20% postsurgical patients who tended to survive, this could cause lower in-hospital mortality compared to other studies [2, 5], and this possibly caused a bias in the interpretation of the results. Fourth, only the MPV within 24 h after intubation was studied, the change of MPV through ICU course were not evaluated due to lacking of data. Fifth, the AUC of 0.848 of MPV > 11.4 fl by ROC curve suggested that MPV alone is not enough to predict mortality. More predictive factors and models should be further studied in future. Sixth, the underlying mechanism of the sex difference between MPV and mortality was not clarified.

Conclusion

The ability of MPV for predicting in-hospital mortality among patients undergoing IMV has not been studied before. The study suggested that MPV is a more useful maker for predicting in-hospital mortality, and MPV > 11.4 fl was an independent predictor factor for in-hospital mortality. This relationship was much stronger in female patients. MPV is reported in routine blood counts with low cost and availability, making it a
profitable marker with immediate clinical applicability, especially in limited resource sites.

Abbreviations
MPV: Mean platelet volume; IMV: Invasive mechanical ventilation; ICU: Intensive care unit; CRP: C-reactive protein; ROC: Receiver-operating characteristics; COPD: Chronic obstructive pulmonary disease; BMI: Body mass index; LOS: Length of stay; APACHE II: Acute physiology and chronic health evaluation II; RR: Respiratory rate; HR: Heart rate; SBP: Systolic blood pressure; Pao2/Fio2: Peripheral oxygen saturation; PaCO2: Arterial carbon dioxide tension; PaO2: Arterial oxygen tension; FiO2: Fraction of inspired oxygen; MPV: Mean platelet volume; PDW: Platelet distribution width; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; AUC: area under the curve; Cl: Confidence interval; HR: Hazard ratio; CRRT: Continuous renal replacement therapy; AKI: Acute kidney injury; CKD: Chronic kidney disease.

Acknowledgements
Not applicable.

Author contributions
YZ and ZL designed the research; ZC conducted the research; YZ and ZL collected and analyzed the data; all authors wrote the paper; and all authors read and approved the final manuscript.

Funding
None.

Availability of data and materials
The data sets supporting the results of this article are included within the article.

Declarations

Ethics approval and consent to participate
This study was approved by the Ethics Committee of the Beijing Chao-Yang Hospital, Capital Medical University. The requirement for informed consent was waived by the Ethics Committee of the Beijing Chao-Yang Hospital, Capital Medical University because of the retrospective nature of the study. All procedures were in accordance with Helsinki Declaration.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Received: 15 July 2022 Accepted: 13 September 2022

Published online: 18 September 2022

References
1. Rackley CR. Monitoring during mechanical ventilation. Respir Care. 2020;65(6):832–46.
2. Vasilyev S, Schaap RN, Mortensen JD. Hospital survival rates of patients with acute respiratory failure in modern respiratory intensive care units. An international, multicenter, prospective survey. Chest. 1995;107(4):1083–8.
3. Ranieri VM, Suter PM, Tortorella C, De Tullio R, Dayer JM, Brienza A, Bruno F, Slutsky AS. Effect of mechanical ventilation on inflammatory mediators in patients with acute respiratory distress syndrome: a randomized controlled trial. JAMA. 1999;282(1):54–61.
4. Behrendt CE. Acute respiratory failure in the United States: incidence and 31-day survival. Chest. 2000;118(4):1100–5.
5. Esteban A, Anzueto A, Frutos F, Alia I, Brochard L, Stewart TE, Benito S, Epstein SK, Apezteguia C, Nighagal P, et al. Characteristics and outcomes in adult patients receiving mechanical ventilation: a 28-day international study. JAMA. 2002;287(3):345–55.
6. Umer M, Juni P, Hansen B, Wettstein MS, Ferguson ND, Fan E. Time-varying intensity of mechanical ventilation and mortality in patients with acute respiratory failure: a registry-based, prospective cohort study. Lancet Respir Med. 2020;8(9):905–13.
7. Chi Y, Zhao Z, French L, Long Y, He H. Prevalence and prognosis of respiratory pendelluft phenomenon in mechanically ventilated ICU patients with acute respiratory failure: a retrospective cohort study. Ann Intensive Care. 2022;12(1):22.
8. Ye Y, Zhu B, Jiang L, Jiang Q, Wang M, Hua L, Xi X. A contemporary assessment of acute mechanical ventilation in Beijing: description, costs, and outcomes. Crit Care Med. 2017;45(7):1160–7.
9. Du B, An Y, Kang Y, Yu X, Zhao M, Ma X, Ai F, Xu Y, Wang Y, Qian C, et al. Characteristics of critically ill patients in ICUs in mainland China. Crit Care Med. 2013;41(1):84–92.
10. Vieira-de-Abreu A, Campbell RA, Weyrich AS, Zimmerman GA. Platelets: versatile effector cells in hemostasis, inflammation, and the immune continuum. Semin Immunopathol. 2012;34(1):5–30.
11. Korniluk A, Koper-Lenkiewicz OM, Kaminska J, Kornona H, Dymicka-Piekarska V. Mean platelet volume (MPV): new perspectives for an old marker in the course and prognosis of inflammatory conditions. Mediators Inflamm. 2019;2019:2913074.
12. Sezgi C, Taylan M, Kaya H, Selimoglu Sen H, Abakay O, Demir M, Abakay A, Tanrikulu AC. Alterations in platelet count and mean platelet volume as predictors of patient outcome in the respiratory intensive care unit. Clin Respir J. 2015;9(4):403–8.
13. Zampieri FG, Ranzani OT, Sabatowski I, de Souza HP, Barbeiro H, da Neto LM, Park M, da Pinheiro SF. An increase in mean platelet volume at admission is associated with higher mortality in critically ill patients. Ann Intensive Care. 2014;4:20.
14. Kim CH, Kim SJ, Lee MJ, Kwon YE, Kim YL, Park KS, Ryu HJ, Park JT, Han SH, Yoo TH, et al. An increase in mean platelet volume from baseline is associated with mortality in patients with severe sepsis or septic shock. PLoS ONE. 2015;10(3):e0119437.
15. Aydemir H, Piskin N, Akduman D, Kokturk F, Aktas E. Platelet and mean platelet volume kinetics in adult patients with sepsis. Platelets. 2015;26(4):331–5.
16. Reangvilaikul T, Udompompaiboon P, Vattanavanit V. Predicting acute respiratory distress syndrome in influenza pneumonia patients using delta mean platelet volume. BMC Pulm Med. 2021;21(1):405.
17. Wang J, Wang L, Jin L, Rong X, Tang X, Guo H, Liu X, Shi L, Tao G. Predictive value of MPV and plasma NT-ProBNP combined with the simplified geneva scale for the prognosis of acute pulmonary embolism. Evid-based Complement Altern Med. eCAM. 2021;2021:1209291.
18. Colakoglu SM, Genc Moralar D, Cekmeceliloglu BT, Hergunsel GO. Relationship of mortality with neutrophil/lymphocyte ratio, platelet/lymphocyte ratio, and mean platelet volume in patients undergoing acute abdominal surgery. Ulus Trauma Acil Cerrahi Derg. 2020;26(5):735–41.
19. Mohamed MF, Ali A, Abbas A, Awad MS, Gouda M, Sediq AM. Mean platelet volume as a predictor of pulmonary hypertension in patients with stable COPD. Int J Chron Obstruct Pulmon Dis. 2019;14:1099–108.
20. Lamirault AC. Alterations in platelet count and mean platelet volume kinetics in adult patients with sepsis. Platelets. 2015;26(4):331–5.
21. Korniluk A, Koper-Lenkiewicz OM, Kaminska J, Kornona H, Dymicka-Piekarska V. Mean platelet volume (MPV): new perspectives for an old marker in the course and prognosis of inflammatory conditions. Mediators Inflamm. 2019;2019:2913074.
22. Sezgi C, Taylan M, Kaya H, Selimoglu Sen H, Abakay O, Demir M, Abakay A, Tanrikulu AC. Alterations in platelet count and mean platelet volume as predictors of patient outcome in the respiratory intensive care unit. Clin Respir J. 2015;9(4):403–8.
23. Zampieri FG, Ranzani OT, Sabatowski I, de Souza HP, Barbeiro H, da Neto LM, Park M, da Pinheiro SF. An increase in mean platelet volume at admission is associated with higher mortality in critically ill patients. Ann Intensive Care. 2014;4:20.
24. Kim CH, Kim SJ, Lee MJ, Kwon YE, Kim YL, Park KS, Ryu HJ, Park JT, Han SH, Yoo TH, et al. An increase in mean platelet volume from baseline is associated with mortality in patients with severe sepsis or septic shock. PLoS ONE. 2015;10(3):e0119437.
25. Aydemir H, Piskin N, Akduman D, Kokturk F, Aktas E. Platelet and mean platelet volume kinetics in adult patients with sepsis. Platelets. 2015;26(4):331–5.
27. Vélez-Páez JL, Legua P, Vélez-Páez P, Irigoyen E, Andrade H, Jara A, López F, Pérez-Galarza J, Baldeón L. Mean platelet volume and mean platelet volume to platelet count ratio as predictors of severity and mortality in sepsis. PLoS ONE. 2022;17(1):e0262356.

28. Chen J, Li Y, Zeng Y, Tian Y, Wen Y, Wang Z. High mean platelet volume associates with in-hospital mortality in severe pneumonia patients. Mediators Inflamm. 2020;2020:8720535.

29. Lee JH, Park M, Han S, Hwang JJ, Park SH, Park SY. An increase in mean platelet volume during admission can predict the prognoses of patients with pneumonia in the intensive care unit: a retrospective study. PLoS ONE. 2018;13(12):e0208715.

30. Hennus MP, van Vuigt AJ, Brabander M, Brus F, Jansen NJ, Bont LJ. Mechanical ventilation drives inflammation in severe viral bronchiolitis. PLoS ONE. 2013;8(12):e83035.

31. Sellares J, Loureiro H, Ferrer M, Amaro R, Farre R, Torres A. The effect of spontaneous breathing on systemic interleukin-6 during ventilator weaning. Eur Respir J. 2012;39(3):654–60.

32. Machlus KR, Thom JN, Italiano JE Jr. Interpreting the developmental dance of the megakaryocyte: a review of the cellular and molecular processes mediating platelet formation. Br J Haematol. 2014;165(2):227–36.

33. Nishimura S, Nagasaki M, Kunishima S, Sawaguchi A, Sakata A, Sakaguchi H, Ohtori M, Matsuoka I, Italiano JE Jr, Ryu T, et al. IL-1α induces thrombopoiesis through megakaryocyte rupture in response to acute platelet needs. J Cell Biol. 2015;209(3):453–66.

34. Butkiewicz AM, Kemona H, Dymicka-Piekarska V, Matowicka-Karna J, Radziwon P, Lipska A. Platelet count, mean platelet volume and thrombocytopoietic indices in healthy women and men. Thromb Res. 2006;118(2):199–204.

35. Johnson M, Ramsey E, Ramwell PW. Sex and age differences in human platelet aggregation. Nature. 1975;253(5490):355–7.

36. Leng XH, Hong SY, Larrucea S, Zhang W, Li TT, López JA, Bray PJ. Platelets of female mice are intrinsically more sensitive to agonists than are platelets of males. Arterioscler Thromb Vasc Biol. 2004;24(2):376–81.

37. Sloan A, Gona P, Johnson AD. Cardiovascular correlates of platelet count and volume in the Framingham Heart Study. Ann Epidemiol. 2015;25(7):492–8.

38. Gremmel T, Kopp CW, Eichelberger B, Koppensteiner R, Panzer S. Sex differences of leukocyte-platelet interactions and on-treatment platelet reactivity in patients with atherosclerosis. Atherosclerosis. 2014;237(2):692–8.

39. Sabettia A, Lombardi L, Stefanini L. Sex differences at the platelet-vascular interface. Intern Emerg Med. 2022;17(5):1267–76.

40. Park BJ, Shim JY, Lee HY, Jung DH, Lee JH, Lee YJ. The relationship of platelet count, mean platelet volume with metabolic syndrome according to the criteria of the American Association of Clinical Endocrinologists: a focus on gender differences. Platelets. 2012;23(1):45–50.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.